Items Tagged ‘dalantercept’

March 1st, 2017

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer

By

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical trial.1 According to investigators, 25% of RCC patients responded to treatment with the combination and this represents an […]

View full entry

Tags: activin receptor–like kinase 1 (ALK1) signaling inhibitor renal cell carcinoma (RCC), dalantercept, News, Renal Cancer


March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

By

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is […]

View full entry

Tags: axitinib, clinical trial, dalantercept, DART study, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, renal cell carcinoma, study